Coherus Oncology CHRS
NASDAQ CHRS
$1.35 +0.02 (+1.89%)
As of: Sep 10, 2026 · 3:59 PM EDT

Coherus Oncology (CHRS) Gross Margin (QoQ) (2019 - 2026)

Analysis

Coherus Oncology (CHRS) Gross Margin (QoQ) (2019 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn
10 Coherus Oncology 209.00 Mn 103.70 Mn 10.07 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 133.00
Mar 31, 2026 75.00
Dec 31, 2025 43.00
Sep 30, 2025 95.00
Jun 30, 2025 180.00
Mar 31, 2025 65.00
Dec 31, 2024 953.00
Sep 30, 2024 -2,752.00
Jun 30, 2024 4,478.00
Mar 31, 2024 3,005.00
Dec 31, 2023 -4,854.00
Sep 30, 2023 -154.00
Jun 30, 2023 970.00
Mar 31, 2023 -2,071.00
Dec 31, 2022 4,625.00
Sep 30, 2022 -5,882.00
Jun 30, 2022 -316.00
Mar 31, 2022 91.00
Dec 31, 2021 929.00
Sep 30, 2021 -674.00